Medtronic annual free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Medtronic Free Cash Flow (FCF) History (MDT)
Medtronic reported $5.43B in free cash flow for fiscal 2026, an increase of 4.65% from the previous fiscal year, with a free cash flow margin of 14.92%.
View full Medtronic company overviewMedtronic free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2026 | 2026-04-24 | $5.43B | $241.0M | +4.65% | +14.92% |
| 2025 | 2025-04-25 | $5.18B | −$15.0M | −0.29% | +15.46% |
| 2024 | 2024-04-26 | $5.20B | $620.0M | +13.54% | +16.07% |
| 2023 | 2023-04-28 | $4.58B | −$1.40B | −23.39% | +14.67% |
| 2022 | 2022-04-29 | $5.98B | $1.09B | +22.37% | +18.87% |
| 2021 | 2021-04-30 | $4.88B | −$1.14B | −18.87% | +16.22% |
| 2020 | 2020-04-24 | $6.02B | $148.0M | +2.52% | +20.82% |
| 2019 | 2019-04-26 | $5.87B | $2.26B | +62.42% | +19.22% |
| 2018 | 2018-04-27 | $3.62B | −$2.01B | −35.73% | +12.07% |
| 2017 | 2017-04-28 | $5.63B | $1.45B | +34.85% | +18.94% |
| 2016 | 2016-04-29 | $4.17B | −$159.0M | −3.67% | +14.47% |
| 2015 | 2015-04-24 | $4.33B | −$232.0M | −5.08% | +21.38% |
| 2014 | 2014-04-25 | $4.56B | $78.0M | +1.74% | +26.83% |
| 2013 | 2013-04-26 | $4.49B | — | — | +27.03% |
Medtronic quarterly free cash flow
Q1.15
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2027 | 2026-07-31 | $1.29B | $706.0M | +120.89% | +13.22% |
| Q4 2026 | 2026-04-24 | $2.08B | $16.0M | +0.77% | +21.26% |
| Q3 2026 | 2026-01-31 | $2.30B | $204.0M | +9.73% | +25.51% |
| Q3 2026 | 2026-01-23 | $2.30B | $204.0M | +9.73% | +25.51% |
| Q2 2026 | 2025-10-24 | $457.0M | −$97.0M | −17.51% | +5.10% |
| Q1 2026 | 2025-07-25 | $584.0M | $118.0M | +25.32% | +6.81% |
| Q4 2025 | 2025-04-25 | $2.07B | −$282.0M | −11.99% | +23.18% |
| Q3 2025 | 2025-01-24 | $2.10B | −$32.0M | −1.50% | +25.28% |
| Q2 2025 | 2024-10-25 | $554.0M | $354.0M | +177.00% | +6.59% |
| Q1 2025 | 2024-07-26 | $466.0M | −$55.0M | −10.56% | +5.89% |
| Q4 2024 | 2024-04-26 | $2.35B | $269.0M | +12.92% | +27.37% |
| Q3 2024 | 2024-01-26 | $2.13B | $886.0M | +71.34% | +26.31% |
| Q2 2024 | 2023-10-27 | $200.0M | −$399.0M | −66.61% | +2.51% |
| Q1 2024 | 2023-07-28 | $521.0M | −$136.0M | −20.70% | +6.76% |
| Q4 2023 | 2023-04-28 | $2.08B | $414.0M | +24.82% | +24.37% |
| Q3 2023 | 2023-01-27 | $1.24B | −$656.0M | −34.56% | +16.07% |
| Q2 2023 | 2022-10-28 | $599.0M | −$899.0M | −60.01% | +7.90% |
| Q1 2023 | 2022-07-29 | $657.0M | −$257.0M | −28.12% | +8.91% |
| Q4 2022 | 2022-04-29 | $1.67B | $300.0M | +21.93% | +20.62% |
| Q3 2022 | 2022-01-28 | $1.90B | −$95.0M | −4.77% | +24.45% |
| Q2 2022 | 2021-10-29 | $1.50B | −$82.0M | −5.19% | +19.09% |
| Q1 2022 | 2021-07-30 | $914.0M | $970.0M | — | +11.44% |
| Q4 2021 | 2021-04-30 | $1.37B | $254.0M | +22.80% | +16.71% |
| Q3 2021 | 2021-01-29 | $1.99B | −$121.0M | −5.72% | +25.63% |
| Q2 2021 | 2020-10-30 | $1.58B | −$4.0M | −0.25% | +20.66% |
| Q1 2021 | 2020-07-31 | −$56.0M | −$1.26B | — | −0.86% |
| Q4 2020 | 2020-04-24 | $1.11B | −$638.0M | −36.42% | +18.57% |
| Q3 2020 | 2020-01-24 | $2.11B | $361.0M | +20.59% | +27.39% |
| Q2 2020 | 2019-10-25 | $1.58B | $627.0M | +65.52% | +20.56% |
| Q1 2020 | 2019-07-26 | $1.21B | −$202.0M | −14.32% | +16.14% |
| Q4 2019 | 2019-04-26 | $1.75B | $1.01B | +134.85% | +21.51% |
| Q3 2019 | 2019-01-25 | $1.75B | $3.0M | +0.17% | +23.23% |
| Q2 2019 | 2018-10-26 | $957.0M | $296.0M | +44.78% | +12.79% |
| Q1 2019 | 2018-07-27 | $1.41B | $952.0M | +207.41% | +19.11% |
| Q4 2018 | 2018-04-27 | $746.0M | −$697.0M | −48.30% | +9.16% |
| Q3 2018 | 2018-01-26 | $1.75B | −$9.0M | −0.51% | +23.75% |
| Q2 2018 | 2017-10-27 | $661.0M | −$543.0M | −45.10% | +9.38% |
| Q1 2018 | 2017-07-28 | $459.0M | −$761.0M | −62.38% | +6.21% |
| Q4 2017 | 2017-04-28 | $1.44B | $470.0M | +48.30% | +18.23% |
| Q3 2017 | 2017-01-27 | $1.76B | $209.0M | +13.48% | +24.15% |
| Q2 2017 | 2016-10-28 | $1.20B | $147.0M | +13.91% | +16.39% |
| Q1 2017 | 2016-07-29 | $1.22B | $628.0M | +106.08% | +17.02% |
| Q4 2016 | 2016-04-29 | $973.0M | — | — | +12.86% |
| Q3 2016 | 2016-01-29 | $1.55B | −$111.0M | −6.68% | +22.35% |
| Q2 2016 | 2015-10-30 | $1.06B | — | — | +14.98% |
| Q1 2016 | 2015-07-31 | $592.0M | $391.0M | +194.53% | +8.14% |
| Q3 2015 | 2015-01-23 | $1.66B | — | — | +38.47% |
| Q1 2015 | 2014-07-25 | $201.0M | — | — | +4.70% |
Medtronic free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $4.88B to $5.43B, a compound annual growth rate of 2.12%. Medtronic's latest reported quarter, Q1 2027, generated $1.29B in free cash flow, an increase of 120.89% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Medtronic source filings ↗Community posts
Medtronic gains cardiac-software clearances across two ablation platforms
Medtronic ($MDT) obtained FDA clearance and a European CE mark for its latest Affera Prism-2 cardiac mapping software, alongside a CE mark for the PulseSelect ProxBox adapter and Proximity Indicator software. The Affera upgrade adds tools f ...
Medtronic’s GI Genius system shows gains in large clinical-practice study
Cosmo reported new results for GI Genius, the AI-assisted endoscopy system it develops and Medtronic ($MDT) commercializes. The cluster-randomized quality-improvement study covered more than 334,000 colonoscopies across 139 US Veterans Heal ...
Medtronic wins FDA clearance for LigaSure instrument on Hugo robot
Medtronic ($MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument for its Hugo robotic-assisted surgery system. The instrument brings the company’s vessel-sealing technology to the robotic platform and is designed to seal ...
Medtronic launches MiniMed share-exchange offer
Medtronic ($MDT) launched an exchange offer to split off at least 80.1% of MiniMed ($MMED), its former diabetes business. Investors can voluntarily exchange Medtronic shares for MiniMed stock at a 7% discount, subject to a cap of 4.5939 Min ...
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...
